{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:34:39Z","timestamp":1768386879608,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc.,"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40264-025-01600-2","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T12:13:40Z","timestamp":1758024820000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Drug Interactions with Enzalutamide in Patients with Prostate Cancer: A Podcast"],"prefix":"10.1007","volume":"49","author":[{"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Looney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judeth","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"3","key":"1600_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1600_CR2","unstructured":"National Cancer Institute. SEER cancer stats facts: prostate cancer. Bethesda, MD. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"Suppl 4","key":"1600_CR3","first-page":"41S","volume":"32","author":"HW Chin","year":"2015","unstructured":"Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in seniors: part 1: epidemiology, pathology, and screening. Fed Pract. 2015;32(Suppl 4):41S-S44.","journal-title":"Fed Pract"},{"issue":"2","key":"1600_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdx742","volume":"29","author":"A Pettersson","year":"2018","unstructured":"Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377\u201385.","journal-title":"Ann Oncol"},{"key":"1600_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74.","journal-title":"BMC Med"},{"issue":"7","key":"1600_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40264-024-01415-7","volume":"47","author":"BW Lennep","year":"2024","unstructured":"Lennep BW, Mack J, Poondru S, Hood E, Looney BD, Williams M, et al. Enzalutamide: understanding and managing drug interactions to improve patient safety and drug efficacy. Drug Saf. 2024;47(7):617\u201341.","journal-title":"Drug Saf"},{"issue":"10","key":"1600_CR7","first-page":"8559","volume":"30","author":"N Tsoukalas","year":"2022","unstructured":"Tsoukalas N, Brito-Dellan N, Font C, Butler T, Rojas-Hernandez CM, Butler T, et al. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Support Care Cancer. 2022;30(10):8559\u201373.","journal-title":"Support Care Cancer"},{"key":"1600_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312808","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222312808.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1600_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10557-023-07453-0","volume":"38","author":"F Boujonnier","year":"2024","unstructured":"Boujonnier F, Lemaitre F, Scailteux LM. Pharmacokinetic interactions between abiraterone, apalutamide, darolutamide or enzalutamide and antithrombotic drugs: prediction of clinical events and review of pharmacological information. Cardiovasc Drugs Ther. 2024;38(4):757\u201367.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"1600_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"1600_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119\u201337.","journal-title":"Annu Rev Med"},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejps.2019.01.024","volume":"130","author":"VM Lauschke","year":"2019","unstructured":"Lauschke VM, Ingelman-Sundberg M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019;130:65\u201377.","journal-title":"Eur J Pharm Sci"},{"key":"1600_CR13","unstructured":"Astellas Pharma Inc. XTANDI prescribing information. 2023."},{"issue":"2","key":"1600_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"key":"1600_CR15","unstructured":"Astellas Pharma Inc. XTANDI summary of product characteristics. 2024."},{"issue":"1","key":"1600_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1600_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/17425255.2022.2122812","volume":"18","author":"D Conde-Estevez","year":"2022","unstructured":"Conde-Estevez D, Henriquez I, Munoz-Rodriguez J, Rodriguez-Vida A. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2022;18(9):601\u201313.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1600_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/UPJ.0000000000000487","volume":"11","author":"B Lowentritt","year":"2024","unstructured":"Lowentritt B, Fallick M, Pruett J, Jiang T, Li E, Brown B, et al. Incidence of cardiovascular events in patients with prostate cancer and treated with androgen deprivation therapy. Urol Pract. 2024;11(1):154\u201361.","journal-title":"Urol Pract"},{"key":"1600_CR19","doi-asserted-by":"publisher","first-page":"175883592199858","DOI":"10.1177\/1758835921998586","volume":"13","author":"F Saad","year":"2021","unstructured":"Saad F, Shore ND. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol. 2021;13:1758835921998586.","journal-title":"Ther Adv Med Oncol"},{"key":"1600_CR20","unstructured":"Sumitomo Pharma Co. ORGOVYX prescribing information. 2023."},{"issue":"3","key":"1600_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.clgc.2023.03.009","volume":"21","author":"DJ George","year":"2023","unstructured":"George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, et al. Impact of concomitant prostate cancer medications on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer. 2023;21(3):383-92e2.","journal-title":"Clin Genitourin Cancer"},{"key":"1600_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100029","volume":"2","author":"A Bellia","year":"2021","unstructured":"Bellia A, Della-Morte D, Di Daniele N, Lauro D. Drug interactions of direct oral anticoagulants in elderly patients with cardiometabolic diseases. Curr Res Pharmacol Drug Discov. 2021;2: 100029.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"1600_CR23","unstructured":"Teva Pharmaceuticals. WARFARIN SODIUM prescribing information. 2021."},{"issue":"5","key":"1600_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/cts.13229","volume":"15","author":"S Poondru","year":"2022","unstructured":"Poondru S, Ghicavii V, Khosravan R, Manchandani P, Heo N, Moy S, et al. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022;15(5):1131\u201342.","journal-title":"Clin Transl Sci"},{"key":"1600_CR25","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. PRADAXA prescribing information. 2023."},{"issue":"2","key":"1600_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285\u201392.","journal-title":"Hypertension"},{"key":"1600_CR27","doi-asserted-by":"publisher","first-page":"1205475","DOI":"10.3389\/fcvm.2023.1205475","volume":"10","author":"SK Masenga","year":"2023","unstructured":"Masenga SK, Kirabo A. Hypertensive heart disease: risk factors, complications and mechanisms. Front Cardiovasc Med. 2023;10:1205475.","journal-title":"Front Cardiovasc Med"},{"key":"1600_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","volume":"26","author":"GC Oh","year":"2020","unstructured":"Oh GC, Cho HJ. Blood pressure and heart failure. Clin Hypertens. 2020;26:1.","journal-title":"Clin Hypertens"},{"issue":"7","key":"1600_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s11864-023-01094-z","volume":"24","author":"E Dolmatova","year":"2023","unstructured":"Dolmatova E, Waheed N, Olson BM, Patel SA, Mandawat A. The intersection of prostate cancer and hypertension: a call to action. Curr Treat Options Oncol. 2023;24(7):892\u2013905.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"1600_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/2042098612474293","volume":"4","author":"RN Lowe","year":"2013","unstructured":"Lowe RN, Marrs JC, Saseen JJ. Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy. Ther Adv Drug Saf. 2013;4(1):9\u201317.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"1600_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117\u201325.","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"1600_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archinte.162.4.405","volume":"162","author":"DA Flockhart","year":"2002","unstructured":"Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162(4):405\u201312.","journal-title":"Arch Intern Med"},{"issue":"14","key":"1600_CR33","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","volume":"97","author":"NJ Brown","year":"1998","unstructured":"Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411\u201320.","journal-title":"Circulation"},{"issue":"19","key":"1600_CR34","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"key":"1600_CR35","first-page":"307","volume":"8","author":"G Leonetti","year":"2012","unstructured":"Leonetti G, Egan CG. Use of carvedilol in hypertension: an update. Vasc Health Risk Manag. 2012;8:307\u201322.","journal-title":"Vasc Health Risk Manag."},{"issue":"9","key":"1600_CR36","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290\u2013314.","journal-title":"Cancer"},{"issue":"8","key":"1600_CR37","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/cancers13081827","volume":"13","author":"M Knura","year":"2021","unstructured":"Knura M, Garczorz W, Borek A, Drzymala F, Rachwal K, George K, et al. The influence of anti-diabetic drugs on prostate cancer. Cancers (Basel). 2021;13(8):1827.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1600_CR38","doi-asserted-by":"publisher","first-page":"18063","DOI":"10.1038\/s41598-018-36212-7","volume":"8","author":"F Yang","year":"2018","unstructured":"Yang F, Liu L, Chen L, Liu M, Liu F, Xiong Y, et al. OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. Sci Rep. 2018;8(1):18063.","journal-title":"Sci Rep"},{"issue":"4","key":"1600_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0976-500X.85934","volume":"2","author":"DJ Dave","year":"2011","unstructured":"Dave DJ. Saxagliptin: a dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother. 2011;2(4):230\u20135.","journal-title":"J Pharmacol Pharmacother"},{"issue":"4","key":"1600_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/jdi.12644","volume":"8","author":"A Kashiwagi","year":"2017","unstructured":"Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8(4):416\u201327.","journal-title":"J Diabetes Investig"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01600-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T05:30:38Z","timestamp":1768368638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01600-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"31 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding was provided by Pfizer Inc. and Astellas Pharma Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have fully considered the Conflicts of Interest policy set forth by the journal. Alicia Morgans has received consulting fees from Astellas Pharma Inc., AAA Pharma Inc., AstraZeneca Pharma LP, Bayer HealthCare Pharma LLC, Curium, Janssen Pharma LLC, Exelixis Inc., Macrogenics, Myovant Sciences, Inc., Merck & Co. Inc., Novartis AG, Lantheus, Telix Pharma Limited, Sanofi S.A., and Pfizer Inc., research fees from Astellas, Bayer HealthCare Pharma LLC, Myovant Sciences Inc., and Pfizer Inc. Brooke Looney receives research support from AstraZeneca Inc. and Pfizer Inc. and has served as a speaker for AstraZeneca Inc. Jesse Mack is an employee of Astellas Pharma Inc. and was a consultant for Pfizer prior to joining Astellas Pharma Inc. Judeth Bianco is an employee of Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human participants or animals by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable, as this article does not contain any studies with human participants by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All co-authors are aware of the submission to this journal, and agree to allow the corresponding author to serve as the primary correspondent with the editorial office and to review and sign off on the final proofs for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Code availability is not applicable as no software application or custom code was used, generated, or analyzed during the current study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors have contributed equally to the manuscript development (i.e., concept and planning of the work described; acquisition, analysis and interpretation of the data; critical review and revision of the manuscript; and approved the final submitted version of the manuscript). All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Editorial support for this podcast was provided by Jack Liao, PhD, at Impact Communication Partners.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing, Editorial, and Other Assistance"}}]}}